Lubazodone

Lubazodone is a serotonin antagonist and reuptake inhibitor (SARI) that was under development by Eli Lilly for the treatment of depression but was never marketed. It acts as a 5-HT2A, 5-HT2C, and 5-HT3 antagonist and serotonin reuptake inhibitor, and also has weak affinity for the alpha-1 and alpha-2 adrenergic and H1 histamine receptors.

History[edit | edit source]

Lubazodone was under development by Eli Lilly in the 1990s for the treatment of depression. However, the development was discontinued and the drug was never marketed.

Pharmacology[edit | edit source]

Lubazodone acts as a 5-HT2A, 5-HT2C, and 5-HT3 antagonist and serotonin reuptake inhibitor. It also has weak affinity for the alpha-1 and alpha-2 adrenergic and H1 histamine receptors.

See also[edit | edit source]

List of investigational antidepressants

Lubazodone Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.